normalized. The number of aligned reads and peaks detected for each sample are shown in Table S1 .
DNase-seq. DNase-seq was performed as previously described (5) . To summarize, nuclei from 5 × 10 7 cells were treated with six different DNase I concentrations (0-12 units) for 10 min at 37°C. The DNase digestion reaction was stopped by adding 50 mM EDTA and subsequently DNA was embedded in 1% low-melt gel agarose plugs. Plugs were incubated overnight at 37°C
in LIDS buffer (1% lithium dodecyl sulfate, 10 mM Tris-HCl [pH 7.5], 100 mM EDTA), washed five times in 50 mM EDTA and stored at 4°C. Pulsed field gel electrophoresis (PFGE) was performed to determine the optimal concentrations of DNase I to be used for DNase-seq. Based on PFGE results, DNA plugs from optimal DNase I concentrations were combined, blunt ended in-gel using T4 DNA polymerase and purified by phenol-chloroform extraction and ethanol precipitation. Biotinylated primers were ligated to the DNase I-treated fragments, digested with MmeI, and captured on streptavidin-coated beads and libraries were prepared for Illumina sequencing. Sequencing was performed using an Illumina GAII, and 35-bp reads were obtained for all samples. Sequences were aligned to the human genome reference sequence (Hg18) using BWA or bowtie (26, 27) and peaks called using MACS (29) . The number of aligned sequence reads is shown in Table S1 .
Identification of VELs.
H3K4me1 peaks identified in each tumor sample were individually compared to those identified in the three normal colon crypt samples. Specifically, H3K4me1 peaks in the tumor and control samples were first combined into a single list, and peaks separated by <11 bp were consolidated. The maximum H3K4me1 signal for each peak was then retrieved for all four samples. Data were quantile normalized to adjust for differences in signal intensity due to read depth. Peaks were then ranked according to the specificity of H3K4me1 signal in the tumor sample using a function of Shannon Entropy (30) . Using rank cutoffs corresponding to approximately 2-fold enrichment or depletion in the cancer sample relative to controls, gained and lost VELs, respectively, were defined. All other putative enhancers were designated control/unchanged enhancers. To estimate the fraction of VELs occurring in regions altered in DNA copy number, SoleSearch was first used to identify genomic regions altered in DNA copy number (31), and these regions were then compared to the location of VELs. Figure S4 . Constructs were transfected in triplicate into V457 cells using Lipofectamine 2000 (Invitrogen). In all instances a renilla luciferase plasmid (pRL-SV40 from Promega) was cotransfected as an internal control. Media was replaced after 24hrs with fresh media and cells were harvested after a total of 48hrs. Luciferase expression levels were determined relative to internal renilla control. Two independent assays were performed. In addition, 5 of these enhancers (numbers 1,3,4,5, and 6 in Figure S4 ) were tested using a reporter construct containing SV40 minimal promoter instead of CEACAM. Gene expression analysis. RNA was purified by cesium chloride density gradient centrifugation from all nine colon cancer cell lines and five independent preparations of epithelial crypt. RNA was then labeled and hybridized to Affymetrix Human Exon 1.0 ST exon arrays according to standard protocols. All microarray data were processed in a single batch using the Affymetrix Expression Console software, obtaining gene level expression data using "core"
Quantification of VEL
probe sets (the highest confidence level probe sets, associated with BLAT alignments of mRNA with annotated full-length CDS regions) using median normalization and the PLIER (probe logarithmic intensity error estimation) algorithm to obtain expression values for 16,952 genes.
Genes located on Y, random, and the mitochondrial chromosomes were excluded. Six genes found by microarray analysis to be altered in expression in multiple CRC lines were validated by
qRT-PCR (fig. S13).
Correlation of VELs to gene expression. Multiple approaches were used to correlate VELs to gene expression. All analyses were performed using algorithms treating the genome in a one dimension linear format, with the underlying assumption that a given VEL could not target a gene promoter if there was a CTCF site, known to block communication between enhancers and promoters (32, 33) , between the two. We took the union of CTCF ChIP-Seq data sets publically available from the ENCODE consortium on five different human cell types (H1hesc, Hsmm, Nhlf, K562, and HepG2), resulting in approximately 34,000 CTCF sites used for our analyses. For all analyses, a CTCF domain was defined as a window centered at the midpoint of VELs or transcription start sites of genes, depending on the specific analysis, extending up to 200KB in both the 5' and 3' directions until/if a CTCF site was reached. First ( Fig. 2A and fig.   S7 ), all genes sharing a CTCF domain with gained or lost VELs, or "VEL genes", were merged back to expression data for which either the median of the five control crypt samples or the cancer sample was above noise (corresponding to a normalized signal intensity value of 30, based on real-time PCR analysis and analysis of the distribution of expression of all genes sampled). Control gene sets were obtained by identifying genes within CTCF domains lacking either gained or lost VELs. Fold-change in expression of VEL and control genes were plotted in a Tukey boxplot, with outliers removed. Significance was determined using Wilcoxon signedrank tests. In the second approach (Fig. 2 ,B and C), Shannon Entropy ranking was used to obtain a list of the top 500 over-expressed and repressed genes in for each individual cell line relative to five control crypts. For over-expressed genes, those below the noise threshold in the cancer sample were filtered out (with no filtering applied to the crypt samples), and for repressed genes, those below the noise threshold in any one of the crypt samples (with no filtering applied to the cancer sample) were filtered out. Gained and lost VELs were subsequently counted within CTCF domains of the over-expressed and repressed genes, respectively. P values reported were generated by a Chi squared test using the average VEL counts of 10 size matched sets of randomly selected genes as the expected fraction and the gained or lost VEL counts as the observed fraction. To address the effect of VELs on individual genes (Fig 2, D and E) , we analyzed the fold change in expression (CRC/median of five crypts)
of genes not sharing a CTCF domain with any other known gene. We required genes to be expressed (signal intensity >80) in either crypts or CRC samples. The threshold of 80 was based on real-time PCR analysis and analysis of the distribution of expression of all genes sampled. Additionally, data were "floored" at the noise threshold, meaning that genes expressed at a normalized value of < 30 were considered 30. . Significance was determined using Wilcoxon signed-rank tests. For the analysis presented in Figure 2F and Figure S9 , we selected gained VEL genes that increased in expression by >1.5 fold in the CRC sample relative to the crypts, and plotted their expression in crypt and the CRC sample in a violin plot.
For lost VELs, genes found to be decreased in expression by >1.5 fold in the CRC relative to the crypts were plotted. For both gained and lost VELs, we required genes to be expressed (signal intensity >80) in either crypts or CRC samples. Moreover, only instances in which a single VEL gene was located within a CTCF domain was considered. Additionally, data were floored at the noise threshold. For the approach presented in Figure S10A , both gained and lost repressed genes associated with each category of common gained and lost VELs, respectively, based on a 1.5 fold cutoff derived from medians of CRC samples and five independent control crypt samples. We then compared the percentage of genes in each group that were similarly overexpressed or repressed in a validation set of 120 primary colon tumors versus 16 normal colon controls (again, using a 1.5 fold cutoff comparing the medians of the tumor and control groups). Significance was determined using the exact binomial test.
Promoter analyses. We identified VEL genes unique to V9M, V503, or V400, and plotted the maximum H3K4me3 and H3K27ac ChIP-seq signals +/-1 kb of the transcription start sites of the VEL genes ( fig. S11 ). To determine whether there are VEL events that occur independently of promoter changes (promoter independent events), we selected all genes that failed to show differences in either H3K4me3 or H3K27ac between CRC samples and the median of 3 crypt samples. We then separated these genes into four groups, (1) those associated with lost VELs, 
